425 related articles for article (PubMed ID: 29337962)
1. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer.
Patel M; McSorley ST; Park JH; Roxburgh CSD; Edwards J; Horgan PG; McMillan DC
Br J Cancer; 2018 Mar; 118(5):705-712. PubMed ID: 29337962
[TBL] [Abstract][Full Text] [Related]
2. Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer.
Park JH; van Wyk H; Roxburgh CSD; Horgan PG; Edwards J; McMillan DC
Br J Cancer; 2017 May; 116(11):1444-1450. PubMed ID: 28427085
[TBL] [Abstract][Full Text] [Related]
3. The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer.
Powell AG; Wallace R; McKee RF; Anderson JH; Going JJ; Edwards J; Horgan PG
Colorectal Dis; 2012 Dec; 14(12):1493-9. PubMed ID: 22507826
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores.
Dolan RD; McSorley ST; Park JH; Watt DG; Roxburgh CS; Horgan PG; McMillan DC
Br J Cancer; 2018 Jul; 119(1):40-51. PubMed ID: 29789606
[TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
[TBL] [Abstract][Full Text] [Related]
6. Determinants of lymph node count and positivity in patients undergoing surgery for colon cancer.
Dolan RD; McSorley ST; Horgan PG; McMillan DC
Medicine (Baltimore); 2018 Mar; 97(13):e0185. PubMed ID: 29595652
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study.
Shida D; Inoue M; Tanabe T; Moritani K; Tsukamoto S; Yamauchi S; Sugihara K; Kanemitsu Y
J Gastroenterol; 2020 Oct; 55(10):958-968. PubMed ID: 32651860
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.
Park JH; Powell AG; Roxburgh CS; Horgan PG; McMillan DC; Edwards J
Br J Cancer; 2016 Mar; 114(5):562-70. PubMed ID: 26859693
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.
Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA
Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898
[TBL] [Abstract][Full Text] [Related]
10. Outcome of right- and left-sided colonic and rectal cancer following surgical resection.
Suttie SA; Shaikh I; Mullen R; Amin AI; Daniel T; Yalamarthi S
Colorectal Dis; 2011 Aug; 13(8):884-9. PubMed ID: 20594201
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients.
Golder AM; McMillan DC; Park JH; Mansouri D; Horgan PG; Roxburgh CS
Br J Cancer; 2021 May; 124(11):1828-1835. PubMed ID: 33762720
[TBL] [Abstract][Full Text] [Related]
12. The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers.
Roxburgh CS; Salmond JM; Horgan PG; Oien KA; McMillan DC
J Gastrointest Surg; 2009 Nov; 13(11):2011-8; discussion 2018-9. PubMed ID: 19768511
[TBL] [Abstract][Full Text] [Related]
13. Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer.
Sarasqueta C; Perales A; Escobar A; Baré M; Redondo M; Fernández de Larrea N; Briones E; Piera JM; Zunzunegui MV; Quintana JM;
BMC Cancer; 2019 Jul; 19(1):735. PubMed ID: 31345187
[TBL] [Abstract][Full Text] [Related]
14. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
Hong SP; Min BS; Kim TI; Cheon JH; Kim NK; Kim H; Kim WH
Eur J Cancer; 2012 May; 48(8):1235-43. PubMed ID: 22071131
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors.
Roxburgh C; McDonald A; Salmond J; Oien K; Anderson J; McKee R; Horgan P; McMillan D
Int J Colorectal Dis; 2011 Apr; 26(4):483-92. PubMed ID: 21212966
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer.
Richards CH; Roxburgh CS; Anderson JH; McKee RF; Foulis AK; Horgan PG; McMillan DC
Br J Surg; 2012 Feb; 99(2):287-94. PubMed ID: 22086662
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer.
Rashtak S; Ruan X; Druliner BR; Liu H; Therneau T; Mouchli M; Boardman LA
Clin Colorectal Cancer; 2017 Jun; 16(2):115-123.e3. PubMed ID: 28365393
[TBL] [Abstract][Full Text] [Related]
18. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy.
Hung HY; Chen JS; Yeh CY; Changchien CR; Tang R; Hsieh PS; Tasi WS; You JF; You YT; Fan CW; Wang JY; Chiang JM
Int J Colorectal Dis; 2011 Aug; 26(8):1059-65. PubMed ID: 21479566
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer.
Wang F; He W; Jiang C; Guo G; Ke B; Dai Q; Long J; Xia L
BMC Cancer; 2018 Nov; 18(1):1102. PubMed ID: 30419863
[TBL] [Abstract][Full Text] [Related]
20. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
